Tazicef Dosage

Generic name: ceftazidime
Dosage form: injection, powder, for solution

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Dosage: The usual adult dosage is 1 gram administered intravenously or intramuscularly every 8 to 12 hours. The dosage and route should be determined by the susceptibility of the causative organisms, the severity of infection, and the condition and renal function of the patient.

The guidelines for dosage of Tazicef (ceftazidime for injection, USP) are listed in Table 3. The following dosage schedule is recommended. 

Table 3. Recommended Dosage Schedule

 

Dose

Frequency

Adults

Usual recommended dosage

Uncomplicated urinary tract infections

Bone and joint infections

Complicated urinary tract infections

Uncomplicated pneumonia; mild skin and skin-

structure infections

Serious gynecologic and

intra-abdominal infections

Meningitis

Very severe life-threatening infections, especially

in immunocompromised patients

Lung infections caused by Pseudomonas spp.

in patients with cystic fibrosis

with normal renal function*

Neonates (0 – 4 weeks)

Infants and children

(1 month – 12 years)

 

1 gram IV or IM

250 mg IV or IM

2 grams IV

500 mg IV or IM

500 mg to 1 gram

IV or IM

2 grams IV

 

2 grams IV

2 grams IV

 

30 to 50 mg/kg IV

to a maximum

of 6 grams per day

30 mg/kg IV

30 to 50 mg/kg IV

to a maximum of 6 grams per day

 

q8-12hr

q12hr

q12hr

q8-12hr

q8hr

 

q8hr

 

q8hr

q8hr

 

q8hr

 

 

q12hr

q8hr

 

* Although clinical improvement has been shown, bacteriologic cures cannot be expected in patients with chronic respiratory disease and cystic fibrosis.

The higher dose should be reserved for immunocompromised pediatric patients or pediatric patients with cystic fibrosis or meningitis.

Impaired Hepatic Function: No adjustment in dosage is required for patients with hepatic dysfunction.

Impaired Renal Function: Ceftazidime is excreted by the kidneys, almost exclusively by glomerular filtration. Therefore, in patients with impaired renal function (glomerular filtration rate [GFR] <50 mL/min), it is recommended that the dosage of ceftazidime be reduced to compensate for its slower excretion. In patients with suspected renal insufficiency, an initial loading dose of 1 gram of ceftazidime may be given. An estimate of GFR should be made to determine the appropriate maintenance dosage. The recommended dosage is presented in Table 4. 

Table 4. Recommended Maintenance Dosages of Tazicef (ceftazidime for injection, USP) in Renal Insufficiency

NOTE: IF THE DOSE RECOMMENDED IN TABLE 3 ABOVE IS LOWER THAN THAT RECOMMENDED FOR PATIENTS WITH RENAL INSUFFICIENCY AS OUTLINED IN TABLE 4, THE LOWER DOSE SHOULD BE USED.

Creatinine

Clearance

(mL/min)

Recommended

Unit Dose of

Tazicef

Frequency

of Dosing

50 – 31

30 – 16

15 – 6

<5

1 gram

1 gram

500 mg

500 mg

q12h

q24h

q24h

q48h

When only serum creatinine is available, the following formula (Cockcroft’s equation)4 may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function:

Males: Creatinine clearance (mL/min) =  [Weight (kg) x (140 - age)] 
 [72 x serum creatinine (mg/dL)]   

Females: 0.85 x male value 

In patients with severe infections who would normally receive 6 grams of Tazicef daily were it not for renal insufficiency, the unit dose given in the table above may be increased by 50% or the dosing frequency may be increased appropriately. Further dosing should be determined by therapeutic monitoring, severity of the infection, and susceptibility of the causative organism.

In pediatric patients as for adults, the creatinine clearance should be adjusted for body surface area or lean body mass, and the dosing frequency should be reduced in cases of renal insufficiency.

In patients undergoing hemodialysis, a loading dose of 1 gram is recommended, followed by 1 gram after each hemodialysis period.

Tazicef (ceftazidime for injection, USP) can also be used in patients undergoing intraperitoneal dialysis and continuous ambulatory peritoneal dialysis. In such patients, a loading dose of 1 gram of Tazicef may be given, followed by 500 mg every 24 hours. In addition to IV use, Tazicef can be incorporated in the dialysis fluid at a concentration of 250 mg for 2 L of dialysis fluid.

Note: Generally Tazicef should be continued for 2 days after the signs and symptoms of infection have disappeared, but in complicated infections longer therapy may be required.

Administration: Tazicef may be given intravenously or by deep IM injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus or lateral part of the thigh. Intra-arterial administration should be avoided (see PRECAUTIONS).

Intramuscular Administration: For IM administration, Tazicef should be reconstituted with one of the following diluents: Sterile Water for Injection, Bacteriostatic Water for Injection, or 0.5% or 1% Lidocaine Hydrochloride Injection. Refer to Table 5.

Intravenous Administration: The IV route is preferable for patients with bacterial septicemia, bacterial meningitis, peritonitis, or other severe or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if shock is present or pending.

For direct intermittent IV administration, reconstitute Tazicef as directed in Table 5 with Sterile Water for Injection. Slowly inject directly into the vein over a period of 3 to 5 minutes or give through the tubing of an administration set while the patient is also receiving one of the compatible IV fluids (see COMPATIBILITY AND STABILITY).

For IV infusion, reconstitute the 1-gram or 2-gram vial and add an appropriate quantity of the resulting solution to an IV container with one of the compatible IV fluids listed under the COMPATIBILITY AND STABILITY section.

Intermittent intravenous infusion with a Y-type administration set can be accomplished with compatible solutions. However, during infusion of a solution containing ceftazidime, it is desirable to discontinue the other solution. 

Table 5. Preparation of Solutions of Tazicef

 

Vial

Size

Amount of

Diluent to

Be Added

 

Approximate

Available Volume

Approximate

Ceftazidime

Concentration

Intramuscular

1 gram

Intravenous Infusion

1 gram

2 gram

3.0 mL

 

10 mL

10 mL

 

3.6 mL

 

10.6 mL

11.2 mL

 

280 mg/mL

 

95 mg/mL

180 mg/mL

All vials of Tazicef as supplied are under reduced pressure. When Tazicef is dissolved, carbon dioxide is released and a positive pressure develops.

Solutions of Tazicef, like those of most beta-lactam antibiotics, should not be added to solutions of aminoglycoside antibiotics because of potential interaction.

However, if concurrent therapy with Tazicef and an aminoglycoside is indicated, each of these antibiotics can be administered separately to the same patient.

Hide
(web2)